期刊
JOURNAL OF CONTROLLED RELEASE
卷 219, 期 -, 页码 383-395出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2015.09.056
关键词
Nanomedicine; Drug delivery
资金
- National Science Foundation [DMR 1255281]
- National Institutes of Health [NIH/1R21CA191740]
- Direct For Mathematical & Physical Scien
- Division Of Materials Research [1255281] Funding Source: National Science Foundation
One-component nanomedicine (OCN) represents an emerging class of therapeutic nanostructures that contain only one type of chemical substance. This one-component feature allows for fine-tuning and optimization of the drug loading and physicochemical properties of nanomedicine in a precise manner through molecular engineering of the underlying building blocks. Using a precipitation procedure or effective molecular assembly strategies, molecularly crafted therapeutic agents (e.g. polymer-drug conjugates, small molecule prodrugs, or drug amphiphiles) could involuntarily aggregate, or self-assemble into nanoscale objects of well-defined sizes and shapes. Unlike traditional carrier-based nanomedicines that are inherently multicomponent systems, an OCN does not require the use of additional carriers and could itself possess desired physicochemical features for preferential accumulation at target sites. We review here recent progress in the molecular design, conjugation methods, and fabrication strategies of OCN, and analyze the opportunities that this emerging platform could open for the new and improved treatment of devastating diseases such as cancer. (C) 2015 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据